NRX PharmaceuticalsNRXP
13F holders, Q3 2024 (September 30)18holders −1
3new positions
4sold out
$1.69avg. 13F price*
At the end of Q3 2024, 18 institutions reported holding NRX Pharmaceuticals Inc. (NRXP) in their 13F filings, down 1 from Q2 2024. 3 opened new positions and 4 sold out. The largest holders were Vanguard Group Inc. ($406K), Anson Funds Management LP ($241K) and AdvisorShares Investments LLC ($220K).
- Company
- NRX Pharmaceuticals Inc.
- CUSIP
- 629444209
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $326K |
| Exits | 4 | $77K |
All 13F filers, Q2 2024 → Q3 2024: 227,473 shares bought and 33,555 shares sold, net +193,918 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Vanguard Group Inc. | 0.00% | No change | 240,316 | $406K |
| Anson Funds Management LP | 0.03% | New | 142,525 | $241K |
| AdvisorShares Investments LLC | 0.04% | Add +20.4% | 130,085 | $220K |
| Geode Capital Management, LLC | 0.00% | Add +17.8% | 77,341 | $131K |
| Sabby Management, LLC | 0.82% | New | 35,049 | $59K |
| BlackRock, Inc. | 0.00% | — | 29,075 | $49K |
| State Street Corp. | 0.00% | No change | 16,724 | $28K |
| One Wealth Management Investment & Advisory Services, LLC | 0.04% | No change | 15,041 | $25K |
| Townsquare Capital LLC | 0.00% | New | 15,041 | $25K |
| Morgan Stanley | 0.00% | No change | 4,396 | $7K |
| Bank of America Corp. | 0.00% | No change | 3,290 | $6K |
| Wells Fargo & Company | 0.00% | Add +77.3% | 2,660 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -23.5% | 2,544 | $4K |
| NewEdge Advisors, LLC | 0.00% | Reduce -85.8% | 83 | $140 |
| JPMorgan Chase & Co. | 0.00% | Add +47.1% | 50 | $84 |
| Harbour Investments, Inc. | 0.00% | No change | 47 | $79 |
| UBS Group AG | 0.00% | Reduce -96.5% | 38 | $64 |
| Larson Financial Group LLC | 0.00% | No change | 22 | $37 |
"% of holder's portfolio" is NRXP's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc. the manager owns.